Page results
-
The psychology team at UCLH are running the next 'Navigating the exam period' group on Wednesday 19 February, from 1pm - 4pm.
-
UCLH has recruited the first participant to an international trial in frontotemporal dementia (FTD), one of the most common causes of early-onset dementia.
-
Swapping the standard blue curtains for sunny yellow ones has made our postnatal ward feel brighter and less clinical.
-
This information is for patients having gynaecology surgery who may also need bowel (colorectal) surgery as part of their cancer treatment.
-
A new study at UCLH and UCL aims to extend survival for some patients with cancer in the biliary tract by treating them with therapies specifically tailored to the genetic profile of their tumour.
-
Arif Ahmed is an entrepreneur and private equity investor in healthcare, technology, e-commerce and B2B services companies. He has a proven track record of scaling innovation in complex regulatory environments.
-
UCLH has recruited the first patient to a global study of a new drug in early development, called NI0752, which is thought to reduce the production of a protein in the brain called tau.
-
This information is for patients receiving steroids for immunotherapy toxicity.
-
This page is for patients receiving steroids for immunotherapy toxicity.
-
Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.
File results
-
FOI/2024/0513 - Robotic platforms for surgery costs/ contract
-
FOI/2024/0514 - Viscosupplementation injections/ spend
-
FOI/2024/0518 - Post partum balloons buying/ usage numbers
-
FOI/2024/0520 - Treatment of melanoma
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0527 - Treatment for renal cell carcinoma
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0395 - Treatment and services for duchenne muscular dystrophy